文献速递药物不良反应与药物警戒

药物性肝损伤风险管理最佳实践的行业综述:从研发到真实世界使用

Industry Review of Best Practices for Risk Management of Drug-Induced Liver Injury from Development to Real-World Use.
PubMed 文献 · Drug Saf · 2023-10-24

本文由IQ-DILI倡议的药物警戒与风险缓解工作组撰写,围绕小分子药物研发期间识别、表征、监测、缓解和沟通DILI风险的三个关键主题展开。文中汇总了DILI表型与严重程度表征、相对治疗获益评估及风险缓解策略实施的最佳实践,并给出标签、REMS或RMP/aRMM的决策指导。报告DILI发生率范围为0.74至19/100,000,Hy's Law病例中至少10%进展为肝衰竭。

要点

  • DILI发生率报告范围为0.74至19/100,000,严重程度由实验室标准或临床结局判定。
  • Hy's Law病例中至少10%进展为肝衰竭,需在研发期充分表征DILI表型。
  • 上市后监测建议取决于研发期表型表征,风险缓解工具包括附加教育及ETASU。

核心结论

  • 风险管理的总体目标是尽可能确保特定产品对个体患者和目标人群的获益大于风险。
  • 需基于研发期DILI表型表征决定上市后监测策略及是否需要REMS或RMP/aRMM。

研究设计与样本

  • IQ-DILI倡议的药物警戒与风险缓解工作组于2016年6月启动,本文为行业最佳实践综述。
  • 围绕小分子药物研发期间DILI风险管理的三个关键主题进行展示与回顾。

主要发现

  • DILI报告发生率范围为0.74至19/100,000。
  • 至少10%的DILI所致黄疸患者(Hy's Law病例)进展为肝衰竭(即严重DILI)。
  • 药物肝脏安全性特征可使用Evaluation of Drug-Induced Serious Hepatotoxicity Plots评估。

关键数值与推荐

  • DILI严重程度由实验室标准和/或临床结局确定。
  • 上市后DILI监测的具体建议取决于研发期间的表型表征。
  • 风险缓解工具包括附加教育机制,风险最小化措施包括面向医疗专业人员、给药场所和患者的ETASU。

临床怎么用

  • 研发期应表征DILI表型、严重程度和发生率,包括识别、预测和恢复。
  • 评估暴露患者的相对治疗获益与DILI风险,结合全球风险缓解策略。
  • 根据患者因素、医疗环境和给药场所、处方者和医疗提供者因素实施风险缓解策略。
  • 评估产品标签是否足以最小化DILI风险,或需FDA REMS或EMA RMP with aRMM。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The relative treatment benefit of a drug for patients during development, marketing authorization review, or after approval includes an assessment of the risk of drug-induced liver injury (DILI). In this article, the Pharmacovigilance and Risk Mitigation Working Group of the IQ-DILI Initiative launched in June 2016 within the International Consortium for Innovation and Quality in Pharmaceutical Development presents and reviews three key topics for essential risk management activities to identify, characterize, monitor, mitigate, and communicate DILI risk associated with small molecules during drug development. The three topics are: (1) Current best practices for characterizing the DILI phenotype and the severity and incidence of DILI in the treatment population, including DILI identification, prediction and recovery. (2) Characterization of the relative treatment benefit for patients who will be exposed to a drug and the attendant risk of DILI in conjunction with existing global risk mitigation strategies. (3) Implementation of risk mitigation strategies during drug development highlighting patient factors, healthcare settings and site of product administration, and prescriber and healthcare provider factors. Industry guidance is provided for assessing whether the product labeling is sufficient to minimize the risk of DILI or whether a United States Food and Drug Administration (FDA) Risk Evaluation and Mitigation Strategy (REMS) or European Medicines Agency (EMA) Risk Management Plan (RMP) with additional Risk Minimization Measures (aRMM) is needed. The relative treatment benefit of a drug for patients during development, marketing authorization review or after approval includes an assessment of the risk of drug-induced liver injury (DILI). Reported incidences of DILI range from 0.74 to 19 per 100,000, and laboratory criteria and/or clinical outcome determine the severity of DILI. At least 10% of patients who develop jaundice caused by DILI (Hy’s Law cases) develop liver failure (i.e., severe DILI). A drug’s liver safety profile can be assessed using Evaluation of Drug-Induced Serious Hepatotoxicity Plots. Specific recommendations for monitoring DILI in the post-marketing setting depend on characterization of the phenotype during drug development. Risk mitigation tools include additional educational mechanisms, and risk minimization measures include Elements To Assure Safe Use (ETASU) for healthcare professionals, administration sites, and patients. The overall aim of risk management is to ensure that the benefit of a particular product exceeds the risks as far as possible for the individual patient and for the target population.

来源:Drug Saf,查看原文。版权归原作者所有。

引用

  1. Marquez L, Raheja R, Chan-Liston M, et al. Industry Review of Best Practices for Risk Management of Drug-Induced Liver Injury from Development to Real-World Use. Drug Saf. 2023. PMID: 37874451. doi:10.1007/s40264-023-01360-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。